(CFTR) Gene Analysis with MCC

Overview

CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Gene Analysis with MCC is a specialized genetic test used to detect disease-causing variants in the CFTR gene, which is associated with Cystic Fibrosis (CF) and related disorders. The test includes Maternal Cell Contamination (MCC) analysis, ensuring the accuracy of prenatal or fetal genetic testing by identifying and accounting for any maternal DNA contamination in the sample.

Why is this Test Done?

• To diagnose or confirm Cystic Fibrosis.
• To identify carriers of CFTR gene mutations.
• For prenatal diagnosis when there is a family history of CF.
• To investigate unexplained infertility, especially congenital absence of the vas deferens in males.
• To support genetic counseling and family planning decisions.
• To ensure fetal DNA results are accurate through MCC testing.

Conditions Associated with CFTR Mutations

• Cystic Fibrosis
• Congenital Bilateral Absence of the Vas Deferens (CBAVD)
• CFTR-Related Metabolic Syndrome (CRMS)
• Certain forms of chronic pancreatitis
• Some respiratory and sinus disorders

Sample Required

• Prenatal samples such as:
  • Chorionic Villus Sampling (CVS)
  • Amniotic Fluid
  • Products of Conception (POC)
• Peripheral blood (for carrier testing)
• Maternal blood sample may be required for MCC analysis

Benefits of MCC Analysis

• Detects maternal DNA contamination in fetal samples.
• Improves reliability of prenatal genetic results.
• Reduces the risk of false-positive or false-negative findings.
• Provides greater confidence in clinical decision-making.

Test Methodology

• DNA Extraction
• Next-Generation Sequencing (NGS) and/or targeted mutation analysis
• Bioinformatics interpretation
• Maternal Cell Contamination (MCC) assessment

Preparation

No special preparation is generally required. Genetic counseling may be recommended before and after testing, particularly for prenatal cases.

Interpretation of Results

• Pathogenic Variant Detected: Indicates a disease-causing CFTR mutation.
• Carrier Status Identified: Individual carries one CFTR mutation but may not have the disease.
• No Significant Variant Detected: No clinically relevant CFTR mutation identified within the test scope.
• MCC Detected: Maternal DNA contamination is present and may require additional interpretation or repeat testing.

Turnaround Time

Typically 2–6 weeks, depending on the laboratory and testing methodology.

Clinical Significance

Early identification of CFTR mutations helps guide diagnosis, treatment planning, reproductive decisions, and prenatal management. The inclusion of MCC analysis enhances the accuracy and reliability of fetal genetic testing results.